Matthew Rabinowitz, Natera Co-Founder and Executive Chairman of the Board, Makes Additional Investment in Natera

Rhea-AI Summary

Natera, Inc. (NASDAQ: NTRA) announced that co-founder and Executive Chairman Matthew Rabinowitz, along with his family's trust, acquired 470,000 shares of the company, investing over $10 million in the last two months. This highlights Rabinowitz's confidence in Natera's mission and future initiatives in women's health, oncology, and transplant. Additionally, executive leaders and non-employee directors have opted for 100% equity compensation for 2022. Roelof Botha, lead independent director, also invested $5 million in Natera stock recently.

Positive

• Matthew Rabinowitz's family trust acquired 470,000 shares, indicating strong insider confidence.
• Rabinowitz has invested over $10 million in Natera, signaling belief in the company's potential.
• Executive leaders opted for 100% equity compensation, aligning interests with shareholders.
• Roelof Botha, lead independent director, recently invested $5 million, suggesting continued institutional faith.

Negative

• None.

AUSTIN, Texas, May 16, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced that Matthew Rabinowitz, co-founder and Executive Chairman of Natera, together with his family's trust, have recently acquired a total of 470,000 shares of Natera stock through the purchase of additional shares on the open market and from the exercise of stock options.

"I am consistently impressed by Natera and its mission, and I am confident that our current initiatives will continue to positively transform women's health, oncology and transplant," said Dr. Rabinowitz. "Natera has established a track record of doing what we set out to do. Our ambitious strategic and technology goals are yielding exceptional results and I am excited by the launches to come. Since we believe the investment is so compelling, over the last two months, my family trust and I have spent over $10 million to increase our ownership in the company."

As previously announced, Natera's executive leaders and non-employee directors have elected to take 100% equity compensation for the remainder of 2022. In addition, in March 2022, Roelof Botha, lead independent director of Natera's board of directors and partner at Sequoia Capital, invested $5 million to purchase shares of Natera's stock on the open market.

About Natera
Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.

Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that the plans, estimates, or expectations contained in such forward-looking statements will be achieved. These forward-looking statements represent expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including: Natera faces numerous uncertainties and challenges in achieving its financial projections and goals; Natera's quarterly results and stock price may fluctuate from period to period; Natera's estimates of market opportunity and forecasts of market growth may prove to be inaccurate; Natera may be unable to compete successfully with existing or future products or services offered by its competitors; Natera may be unable to develop and successfully commercialize new products; and Natera's existing and any new products may not meet the expectations of patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.investor.natera.com and www.sec.gov.

Contacts
Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350
Media: Kate Stabrawa, Communications, Natera, Inc., pr@natera.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/matthew-rabinowitz-natera-co-founder-and-executive-chairman-of-the-board-makes-additional-investment-in-natera-301547776.html

SOURCE Natera, Inc.

FAQ

What recent investment did Matthew Rabinowitz make in Natera (NTRA)?

Matthew Rabinowitz acquired 470,000 shares of Natera stock, investing over $10 million.

What does Matthew Rabinowitz say about Natera's future?

He expressed confidence in Natera's initiatives in women's health, oncology, and transplant.

What equity compensation decision was made by Natera's executive leaders in 2022?

Natera's executive leaders and non-employee directors opted for 100% equity compensation for the remainder of 2022.

How much did Roelof Botha invest in Natera?

Roelof Botha invested $5 million to purchase shares of Natera.

What is the significance of the recent stock purchases by Natera executives?

These purchases reflect strong insider confidence and alignment with shareholder interests.